The following is a summary of “Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic ...

SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of artificial intelligence (AI)-based solutions for skin is excited to announce the publication of a case study highlighting the use of ...

Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

Enveda, a biotechnology company using AI to translate nature into new medicines, announced today that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) ...

Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

ZORYVE cream, 0.15%, is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients ... ZORYVE is for topical use only and not for ophthalmic, oral, or ...

The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

Some clinicians may choose to initiate treatment of atopic dermatitis with topical corticosteroids ... Taking into consideration that systemically administered (oral) calcineurin inhibitors ...

He is spearheading the Danish Atopic Dermatitis Register for Systemic Treatment (SCRATCH) and providing strategic consultations and advice for the pharmaceutical industry based on his extensive ...

Top-line results show that 64.7% of patients achieved clear or almost clear skin measured using the Investigator's Global ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.